Oryzon Genomics Statistics

Total Valuation

Oryzon Genomics has a market cap or net worth of EUR 93.96 million. The enterprise value is 101.94 million.

Market Cap	93.96M
Enterprise Value	101.94M

Important Dates

The next estimated earnings date is Wednesday, February 26, 2025.

Earnings Date	Feb 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Oryzon Genomics has 64.71 million shares outstanding. The number of shares has increased by 8.99% in one year.

Current Share Class	n/a
Shares Outstanding	64.71M
Shares Change (YoY)	+8.99%
Shares Change (QoQ)	+0.70%
Owned by Insiders (%)	10.29%
Owned by Institutions (%)	0.14%
Float	54.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	66.91
PS Ratio	6.49
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-24.96
EV / Sales	7.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-0.02

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Capital (ROIC)	n/a
Revenue Per Employee	308,513
Profits Per Employee	-88,795
Employee Count	46
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.29% in the last 52 weeks. The beta is 0.67, so Oryzon Genomics's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-21.29%
50-Day Moving Average	1.55
200-Day Moving Average	1.78
Relative Strength Index (RSI)	42.02
Average Volume (20 Days)	164,342

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oryzon Genomics had revenue of EUR 14.19 million and -4.08 million in losses. Loss per share was -0.06.

Revenue	14.19M
Gross Profit	13.95M
Operating Income	-41,045
Pretax Income	-6.84M
Net Income	-4.08M
EBITDA	82,356
EBIT	-41,045
Loss Per Share	-0.06

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 98.28%, with operating and profit margins of -0.29% and -28.78%.

Gross Margin	98.28%
Operating Margin	-0.29%
Pretax Margin	-48.17%
Profit Margin	-28.78%
EBITDA Margin	0.58%
EBIT Margin	-0.29%
FCF Margin	n/a

Dividends & Yields

Oryzon Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.99%
Shareholder Yield	-8.99%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a